PT2069324E - Amino piridina fundida como inibidor da hsp90 - Google Patents
Amino piridina fundida como inibidor da hsp90Info
- Publication number
- PT2069324E PT2069324E PT87437554T PT08743755T PT2069324E PT 2069324 E PT2069324 E PT 2069324E PT 87437554 T PT87437554 T PT 87437554T PT 08743755 T PT08743755 T PT 08743755T PT 2069324 E PT2069324 E PT 2069324E
- Authority
- PT
- Portugal
- Prior art keywords
- amino pyridine
- hsp90 inhibitors
- fused amino
- hsp90
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89592107P | 2007-03-20 | 2007-03-20 | |
| US1528807P | 2007-12-20 | 2007-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2069324E true PT2069324E (pt) | 2013-10-10 |
Family
ID=39766345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT87437554T PT2069324E (pt) | 2007-03-20 | 2008-03-10 | Amino piridina fundida como inibidor da hsp90 |
Country Status (24)
| Country | Link |
|---|---|
| US (10) | US8324240B2 (https=) |
| EP (1) | EP2069324B1 (https=) |
| JP (1) | JP5401329B2 (https=) |
| KR (1) | KR101313804B1 (https=) |
| CN (1) | CN101679347B (https=) |
| AU (1) | AU2008229216B2 (https=) |
| BR (1) | BRPI0808301B1 (https=) |
| CA (1) | CA2680778C (https=) |
| CY (1) | CY1114507T1 (https=) |
| DK (1) | DK2069324T3 (https=) |
| EA (1) | EA019103B1 (https=) |
| ES (1) | ES2430217T3 (https=) |
| HR (1) | HRP20130910T1 (https=) |
| IL (2) | IL200924A (https=) |
| MX (1) | MX2009009936A (https=) |
| MY (1) | MY148860A (https=) |
| NZ (1) | NZ579635A (https=) |
| PL (1) | PL2069324T3 (https=) |
| PT (1) | PT2069324E (https=) |
| RS (1) | RS52978B (https=) |
| SI (1) | SI2069324T1 (https=) |
| TW (1) | TWI471131B (https=) |
| WO (1) | WO2008115719A1 (https=) |
| ZA (1) | ZA200906371B (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070129334A1 (en) * | 2001-10-30 | 2007-06-07 | Conforma Therapeutics Corporation | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US7834181B2 (en) * | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US10336757B2 (en) * | 2006-06-30 | 2019-07-02 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibition of HSP90 |
| EP2061772A4 (en) * | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
| US20080234297A1 (en) * | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
| JP5401329B2 (ja) * | 2007-03-20 | 2014-01-29 | キュリス，インコーポレイテッド | Ｈｓｐ９０インヒビターとしての縮合アミノピリジン |
| EP2469399B1 (en) | 2008-02-11 | 2019-09-11 | Idean Enterprises Oy | Layer-based user interface |
| US8017780B1 (en) | 2008-10-09 | 2011-09-13 | Myrexis, Inc. | Therapeutic compounds and uses thereof |
| CA2786715C (en) | 2009-01-16 | 2019-05-21 | Curis, Inc. | Fused amino pyridines for the treatment of brain tumors |
| TWI460177B (zh) | 2009-07-10 | 2014-11-11 | Taiho Pharmaceutical Co Ltd | An azabicyclo compound or a salt thereof |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| WO2011044394A1 (en) * | 2009-10-07 | 2011-04-14 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| AU2013204109B2 (en) * | 2009-10-07 | 2016-05-05 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| EP2542687A1 (en) * | 2010-03-05 | 2013-01-09 | Baylor Research Institute | Involvement of androgen/androgen receptor pathway in fabry disease |
| WO2012131413A1 (en) * | 2011-03-25 | 2012-10-04 | Debiopharm Sa | Crystalline forms of fused amino pyridines as hsp90 inhibitors |
| ES2647889T3 (es) * | 2011-04-05 | 2017-12-27 | Sloan-Kettering Institute For Cancer Research | Inhibidores de la Hsp90 |
| WO2012138894A1 (en) | 2011-04-05 | 2012-10-11 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| WO2012147084A2 (en) * | 2011-04-26 | 2012-11-01 | Rdd Pharma Ltd. | Oxymetazoline for the treatment of ano-rectal disorders |
| SMT201900660T1 (it) | 2012-02-09 | 2020-01-14 | Univ Kansas | Inibitori c-terminali di hsp90 |
| MX2014014188A (es) | 2012-05-25 | 2015-05-11 | Berg Llc | Metodos para tratar un sindrome metaboilico mediante la modulacion de la proteina de choque termico (hsp) 90-beta. |
| US10201623B2 (en) | 2013-03-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
| TW201533043A (zh) * | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| JP6539275B2 (ja) | 2013-08-16 | 2019-07-03 | メモリアル スローン ケタリング キャンサー センター | 選択的ｇｒｐ９４阻害剤およびその使用 |
| MX2016008418A (es) | 2013-12-23 | 2017-01-11 | Memorial Sloan Kettering Cancer Center | Metodos y reactivos para el radiomarcaje. |
| US10023864B2 (en) | 2014-06-06 | 2018-07-17 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| MX388516B (es) * | 2014-06-24 | 2025-03-20 | Univ Kansas | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70. |
| CN113521314A (zh) | 2014-09-17 | 2021-10-22 | 纪念斯隆-凯特琳癌症中心 | Hsp90-靶向炎症和感染成像及治疗 |
| LT3319959T (lt) | 2015-07-06 | 2021-12-27 | Alkermes, Inc. | Histono deacetilazės hetero-halogeno inhibitoriai |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| RS62959B1 (sr) | 2017-01-11 | 2022-03-31 | Alkermes Inc | Biciklični inhibitori histon-deacetilaze |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| EP3600376A1 (en) | 2017-03-31 | 2020-02-05 | Alma Bio Therapeutics | Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same |
| US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
| JP7508375B2 (ja) | 2018-05-14 | 2024-07-01 | リアタ ファーマシューティカルズ インコーポレイテッド | 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| CA3125900A1 (en) | 2019-01-08 | 2020-07-16 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitor |
| US12304897B2 (en) | 2019-01-31 | 2025-05-20 | Kyorin Pharmaceutical Co., Ltd. | 15-PGDH inhibitors |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| GB202006382D0 (en) | 2020-04-30 | 2020-06-17 | Spermatech As | Use |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| WO2023006993A1 (en) | 2021-07-30 | 2023-02-02 | Atmosr | Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome |
| WO2024076731A1 (en) * | 2022-10-06 | 2024-04-11 | Regranion, Llc | Methods and compositions for treating hidradenitis suppurativa |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| AU2024296650A1 (en) * | 2023-07-10 | 2026-02-19 | Regranion, Llc | Methods and compositions for treating atopic dermatitis |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025080629A1 (en) * | 2023-10-10 | 2025-04-17 | Regranion, Llc | Methods and compositions for treating behçet's disease |
| WO2025080623A1 (en) * | 2023-10-10 | 2025-04-17 | Regranion, Llc | Methods and compositions for treating discoid lupus erythematosus, systemic lupus erythematosus, and subacute cutaneous lupus erythematosus |
| WO2025080645A1 (en) * | 2023-10-10 | 2025-04-17 | Regranion, Llc | Methods and compositions for treating bullous pemphigoid |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217284A1 (en) * | 2024-04-09 | 2025-10-16 | Regranion, Llc | Methods and compositions for treating inflammatory and autoimmune disorders of the skin |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0708772B1 (en) * | 1993-07-15 | 2000-08-23 | Minnesota Mining And Manufacturing Company | IMIDAZO [4,5-c]PYRIDIN-4-AMINES |
| US5644063A (en) * | 1994-09-08 | 1997-07-01 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]pyridin-4-amine intermediates |
| US6723727B1 (en) * | 1996-12-20 | 2004-04-20 | Hoechst Aktiengesellschaft | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them |
| TR200002182T2 (tr) * | 1998-01-27 | 2000-12-21 | Aventis Pharmaceuticals Products Inc. | İkame edilmiş aksozaherosayklil faktör xa inhibitörleri |
| WO2000038683A1 (en) * | 1998-12-23 | 2000-07-06 | Du Pont Pharmaceuticals Company | THROMBIN OR FACTOR Xa INHIBITORS |
| US6841549B1 (en) * | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| SK1182002A3 (en) * | 1999-07-28 | 2002-11-06 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl compounds |
| US20020045613A1 (en) * | 2000-04-27 | 2002-04-18 | Heinz Pauls | 1-aroyl-piperidinyl benzamidines |
| JP2005519848A (ja) * | 2000-11-02 | 2005-07-07 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Ｈｓｐ９０に結合するための小分子組成物 |
| ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
| US7241890B2 (en) * | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
| WO2004072081A1 (en) * | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
| CA2518318A1 (en) * | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1646614A4 (en) * | 2003-07-01 | 2008-09-10 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
| KR20060070572A (ko) * | 2003-09-18 | 2006-06-23 | 콘포마 세러퓨틱스 코포레이션 | Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물 |
| AU2004274309B2 (en) | 2003-09-22 | 2010-04-08 | Msd K.K. | Novel piperidine derivative |
| US20080015184A1 (en) * | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
| US20070259881A1 (en) * | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
| WO2006029115A2 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1h imidazo ring systems and methods |
| GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| JP5033119B2 (ja) * | 2005-04-25 | 2012-09-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナーゼ阻害剤としての新規アザ複素環化合物 |
| US20070105874A1 (en) * | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
| EP1962863A4 (en) * | 2005-12-22 | 2010-11-24 | Conforma Therapeutics Corp | ORALLY ACTIVE PURINE INHIBITORS OF THERMAL SHOCK PROTEIN 90 |
| US20070253896A1 (en) * | 2006-02-07 | 2007-11-01 | Conforma Therapeutics Corporation | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors |
| WO2007093901A1 (en) | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as tlr7 modulators |
| WO2007134298A2 (en) * | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
| US10336757B2 (en) | 2006-06-30 | 2019-07-02 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibition of HSP90 |
| EP2061772A4 (en) * | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
| CN101573333B (zh) | 2006-10-28 | 2013-06-12 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| JP5401329B2 (ja) * | 2007-03-20 | 2014-01-29 | キュリス，インコーポレイテッド | Ｈｓｐ９０インヒビターとしての縮合アミノピリジン |
| US20080234297A1 (en) * | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
| CA2786715C (en) | 2009-01-16 | 2019-05-21 | Curis, Inc. | Fused amino pyridines for the treatment of brain tumors |
-
2008
- 2008-03-10 JP JP2009554633A patent/JP5401329B2/ja active Active
- 2008-03-10 DK DK08743755.4T patent/DK2069324T3/da active
- 2008-03-10 WO PCT/US2008/056396 patent/WO2008115719A1/en not_active Ceased
- 2008-03-10 SI SI200831049T patent/SI2069324T1/sl unknown
- 2008-03-10 ES ES08743755T patent/ES2430217T3/es active Active
- 2008-03-10 PT PT87437554T patent/PT2069324E/pt unknown
- 2008-03-10 EP EP08743755.4A patent/EP2069324B1/en active Active
- 2008-03-10 KR KR1020097021910A patent/KR101313804B1/ko active Active
- 2008-03-10 MY MYPI20093837A patent/MY148860A/en unknown
- 2008-03-10 EA EA200901263A patent/EA019103B1/ru unknown
- 2008-03-10 CA CA2680778A patent/CA2680778C/en active Active
- 2008-03-10 US US12/045,509 patent/US8324240B2/en active Active
- 2008-03-10 PL PL08743755T patent/PL2069324T3/pl unknown
- 2008-03-10 BR BRPI0808301-0A patent/BRPI0808301B1/pt active IP Right Grant
- 2008-03-10 NZ NZ579635A patent/NZ579635A/en unknown
- 2008-03-10 CN CN200880016525.7A patent/CN101679347B/zh active Active
- 2008-03-10 RS RS20130434A patent/RS52978B/sr unknown
- 2008-03-10 AU AU2008229216A patent/AU2008229216B2/en active Active
- 2008-03-10 HR HRP20130910AT patent/HRP20130910T1/hr unknown
- 2008-03-10 MX MX2009009936A patent/MX2009009936A/es active IP Right Grant
- 2008-03-13 TW TW97108801A patent/TWI471131B/zh active
-
2009
- 2009-09-14 ZA ZA200906371A patent/ZA200906371B/xx unknown
- 2009-09-14 IL IL200924A patent/IL200924A/en active IP Right Grant
-
2012
- 2012-03-20 US US13/424,780 patent/US8586605B2/en active Active
-
2013
- 2013-10-15 US US14/054,273 patent/US9040556B2/en active Active
- 2013-10-17 CY CY20131100916T patent/CY1114507T1/el unknown
-
2015
- 2015-01-26 IL IL236938A patent/IL236938A0/en unknown
- 2015-04-08 US US14/681,310 patent/US9402832B2/en active Active
-
2016
- 2016-07-01 US US15/200,232 patent/US9630965B2/en active Active
-
2017
- 2017-03-30 US US15/474,248 patent/US10035797B2/en active Active
-
2018
- 2018-07-11 US US16/032,282 patent/US10428068B2/en active Active
-
2019
- 2019-08-28 US US16/553,764 patent/US10844056B2/en active Active
-
2020
- 2020-10-29 US US17/083,964 patent/US11560377B2/en active Active
-
2022
- 2022-12-15 US US18/081,966 patent/US20230192687A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY148860A (en) | Fused amino pyridine as hsp90 inhibitors | |
| PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| IL184617A0 (en) | Dr5 antibodies and uses thereof | |
| EP4269563A3 (en) | Anti-gd2 antibodies | |
| MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
| MX337590B (es) | Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias. | |
| MX2007009807A (es) | Agentes terapeuticos de aptameros utiles en el tratamiento de trastornos relacionados con el complemento. | |
| MX2011009539A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso. | |
| EP2614085A4 (en) | ANTI-IL-1 ANTIBODIES AND METHOD FOR THEIR USE | |
| UA105290C2 (ru) | АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ | |
| WO2009012176A3 (en) | Methods and compositions for treating brain diseases | |
| SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
| WO2012149478A3 (en) | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| WO2011143624A3 (en) | Humanized and chimeric monoclonal antibodies to cd47 | |
| TW200716646A (en) | (S)-N-methylnaltrexone | |
| TW200740844A (en) | Novel MAdCAM antibodies | |
| GEP20217253B (en) | ANTIBODIES TO α-SYNUCLEIN AND USES THEREOF | |
| MX2010005651A (es) | Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento. | |
| MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| EP2175879A4 (en) | TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN | |
| WO2010091384A3 (en) | Cadherin-11 inhibitors and methods of use thereof | |
| TW200801038A (en) | Immunoglobulins | |
| WO2009074253A3 (en) | Clofarabine dietherphospholipid derivatives | |
| UA104275C2 (en) | Fused amino pyridine ashsp90 inhibitor |